HansBiomed Corporation (KOSDAQ:042520)

South Korea flag South Korea · Delayed Price · Currency is KRW
33,150
+2,950 (9.77%)
At close: Apr 27, 2026
356.61%
Market Cap 443.53B
Revenue (ttm) 100.17B
Net Income (ttm) -27.44B
Shares Out 14.26M
EPS (ttm) -2,097.10
PE Ratio n/a
Forward PE 29.28
Dividend n/a
Ex-Dividend Date n/a
Volume 345,079
Average Volume 215,354
Open 31,000
Previous Close 30,200
Day's Range 31,000 - 34,100
52-Week Range 6,850 - 57,800
Beta 2.42
RSI 41.04
Earnings Date May 15, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 297
Stock Exchange KOSDAQ
Ticker Symbol 042520
Full Company Profile

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.

Financial Statements

News

There is no news available yet.